{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ER+Positive&page=12", "query": { "condition": "ER Positive", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 418, "total_pages": 42, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ER+Positive&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ER+Positive&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T07:36:46.023Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03289039", "title": "Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Neratinib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 21, "start_date": "2017-10-25", "completion_date": "2021-07-20", "has_results": true, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-11-14T07:36:46.023Z", "location_count": 6, "location_summary": "Indianapolis, Indiana • Brewer, Maine • Boston, Massachusetts + 3 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Brewer", "state": "Maine" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Londonderry", "state": "New Hampshire" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03289039" }, { "nct_id": "NCT02938442", "title": "Vaccination of Triple Negative Breast Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer", "Breast Neoplasms" ], "interventions": [ { "name": "P10s-PADRE with MONTANIDE™ ISA 51 VG", "type": "BIOLOGICAL" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 16, "start_date": "2019-01-25", "completion_date": "2023-01-09", "has_results": true, "last_update_posted_date": "2024-11-07", "last_synced_at": "2026-11-14T07:36:46.023Z", "location_count": 2, "location_summary": "Fayetteville, Arkansas • Little Rock, Arkansas", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02938442" }, { "nct_id": "NCT00546156", "title": "Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ian E. Krop, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2007-10", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2021-05-18", "last_synced_at": "2026-11-14T07:36:46.023Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Hooksett, New Hampshire", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hooksett", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00546156" }, { "nct_id": "NCT06401889", "title": "Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anatomic Stage 0 Breast Cancer AJCC v8", "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Breast Adenocarcinoma", "Estrogen Receptor-Positive Breast Carcinoma", "Progesterone Receptor-Positive Breast Carcinoma" ], "interventions": [ { "name": "Non-Interventional Study", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 35, "start_date": "2024-07-19", "completion_date": "2027-07-19", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-11-14T07:36:46.023Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06401889" }, { "nct_id": "NCT06184750", "title": "Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Atypical Ductal Hyperplasia", "Breast Atypical Lobular Hyperplasia", "Breast Carcinoma", "Breast Ductal Carcinoma In Situ", "Breast Lobular Carcinoma In Situ", "Estrogen Receptor-Positive Breast Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Mammography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Tamoxifen", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "18 Years to 55 Years · Female only" }, "enrollment_count": 200, "start_date": "2024-09-27", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-11-14T07:36:46.023Z", "location_count": 11, "location_summary": "Tucson, Arizona • Chicago, Illinois • Kansas City, Kansas + 6 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06184750" }, { "nct_id": "NCT02409316", "title": "[18F]FES PET/CT in Endocrine Refractory Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor Positive Breast Cancer", "Breast Neoplasm", "Metastatic Breast Cancer" ], "interventions": [ { "name": "[18F]FES", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 6, "start_date": "2015-10-15", "completion_date": "2025-08-01", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-11-14T07:36:46.023Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02409316" }, { "nct_id": "NCT01674140", "title": "S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "anastrozole", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" }, { "name": "exemestane", "type": "DRUG" }, { "name": "goserelin acetate", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "leuprolide acetate", "type": "DRUG" }, { "name": "tamoxifen citrate", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1939, "start_date": "2013-09-12", "completion_date": "2030-01", "has_results": true, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-11-14T07:36:46.023Z", "location_count": 1454, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 888 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01674140" }, { "nct_id": "NCT02712723", "title": "Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Letrozole", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Qamar Khan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 121, "start_date": "2016-02", "completion_date": "2026-12", "has_results": true, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-11-14T07:36:46.023Z", "location_count": 13, "location_summary": "Little Rock, Arkansas • Duarte, California • Santa Ana, California + 9 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02712723" }, { "nct_id": "NCT03822468", "title": "Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "FEMALE", "summary": "18 Years to 100 Years · Female only" }, "enrollment_count": 376, "start_date": "2019-06-11", "completion_date": "2024-08-30", "has_results": true, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-11-14T07:36:46.023Z", "location_count": 14, "location_summary": "Mobile, Alabama • Greenbrae, California • Longmont, Colorado + 11 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Greenbrae", "state": "California" }, { "city": "Longmont", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03822468" }, { "nct_id": "NCT01723774", "title": "PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "PD0332991", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Surgery (standard of care)", "type": "PROCEDURE" }, { "name": "Tumor biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 84, "start_date": "2013-04-10", "completion_date": "2027-11-07", "has_results": true, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-11-14T07:36:46.023Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Rochester, Minnesota + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01723774" } ] }